Read by QxMD icon Read

Biology of Blood and Marrow Transplantation

R Frank Cornell, Luciano J Costa
No abstract text is available yet for this article.
November 15, 2018: Biology of Blood and Marrow Transplantation
Mini Kamboj, Nina Cohen, Yao-Ting Huang, Marina Kerpelev, Ann Jakubowski, Kent A Sepkowitz, Genovefa A Papanicolaou, Susan K Seo
In recent years, vancomycin-resistant Enterococcus (VRE) colonization is increasingly being encountered among transplant populations, and VRE has become one of the leading causes of bacteremia early after allogeneic hematopoietic stem cell transplantation (allo-HSCT). There are sparse data regarding the effect of empiric VRE therapy for febrile, neutropenic allo-HSCT recipients colonized with VRE. All allo-HSCT patients aged 18 years and older who developed VRE bacteremia (VREB) between 2005-2014 were identified and categorized as to whether they received empiric versus (vs) directed VRE therapy...
November 15, 2018: Biology of Blood and Marrow Transplantation
Jacob Rozmus, Amina Kariminia, Sayeh Abdossamadi, Barry E Storer, Paul J Martin, Stephanie J Lee, Daniel Wolff, Mukta Arora, Corey Cutler, Kirk R Schultz
Previous studies have reported single B cell related chronic graft-versus-host disease diagnostic (cGvHD) biomarkers such as B cell activating factor (BAFF), CD21low and immature B cells, but research on the performance of biomarker combinations and the covariate effect of steroids is lacking. The primary objective of this study was to determine the most accurate combination of B cell populations using cell surface staining flow cytometry in an independent cGvHD cohort. Secondary objectives included assessing the effect of corticosteroid use at sample collection on the make-up and accuracy of the diagnostic panel and identifying the mechanism underlying low surface expression of BAFF receptor (BAFF-R) on B cells in cGvHD...
November 14, 2018: Biology of Blood and Marrow Transplantation
Mary Riwes, Pavan Reddy
No abstract text is available yet for this article.
November 12, 2018: Biology of Blood and Marrow Transplantation
Claudio G Brunstein, Marcelo C Pasquini, Soyoung Kim, Mingwei Fei, Kehinde Adekola, Ibrahim Ahmed, Mahmoud Aljurf, Vaibhav Agrawal, Jeffrey J Auletta, Minoo Battiwalla, Nelli Bejanyan, Joseph Bubalo, Jan Cerny, Lynette Chee, Stefan O Ciurea, Cesar Freytes, Shahinaz M Gadalla, Robert Peter Gale, Siddhartha Ganguly, Shahrukh K Hashmi, Peiman Hematti, Gerhard Hildebrandt, Leona A Holmberg, Oscar B Lahoud, Heather Landau, Hillard M Lazarus, Marcos de Lima, Vikram Mathews, Richard Maziarz, Taiga Nishihori, Maxim Norkin, Richard Olsson, Ran Reshef, Seth Rotz, Bipin Savani, Harry C Schouten, Sachiko Seo, Baldeep M Wirk, Jean Yared, Shin Mineishi, John Rogosheske, Miguel-Angel Perales
There are limited data on whether to adjust high-dose chemotherapy prior to autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m2 . Dose adjustment was defined as a reduction in standard dosing of ≥ 20%, based on ideal, reported dosing and actual weights. We included two groups of US patients who had received autoHCT between 2008 and 2014. Specifically, we included patients with multiple myeloma (MM, n=1696) treated with high-dose melphalan; and we included patients with Hodgkin or non-Hodgkin lymphomas (n=781) who received carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning...
November 10, 2018: Biology of Blood and Marrow Transplantation
Michael A Pulsipher, Brent R Logan, Pintip Chitphakdithai, Deidre M Kiefer, Marcie L Riches, J Douglas Rizzo, Paolo Anderlini, Susan F Leitman, James W Varni, Hati Kobusingye, RaeAnne M Besser, John P Miller, Rebecca J Drexler, Aly Abdel-Mageed, Ibrahim A Ahmed, Luke P Akard, Andrew S Artz, Edward D Ball, Ruthee-Lu Bayer, Carolyn Bigelow, Brian J Bolwell, E Randolph Broun, Nancy J Bunin, David C Delgado, Katharine Duckworth, Christopher C Dvorak, Theresa E Hahn, Ann E Haight, Parameswaran N Hari, Brandon M Hayes-Lattin, David A Jacobsohn, Ann A Jakubowski, Kimberly A Kasow, Hillard M Lazarus, Jane L Liesveld, Michael Linenberger, Mark R Litzow, Walter Longo, Margarida Magalhaes-Silverman, John M McCarty, Joseph P McGuirk, Shahram Mori, Vinod K Prasad, Scott D Rowley, Witold B Rybka, Indira Sahdev, Jeffrey R Schriber, George B Selby, Paul J Shaughnessy, Shalini Shenoy, Thomas Spitzer, William T Tse, Joseph P Uberti, Madhuri Vusirikala, Edmund K Waller, Daniel J Weisdorf, Gregory A Yanik, Willis H Navarro, Mary M Horowitz, Galen E Switzer, Bronwen E Shaw, Dennis L Confer
The development of reduced intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers of older related donors (RD) of PBSC. The effects of age on donation efficacy, toxicity, and long-term recovery in RD are poorly understood. To address this we analyzed hematologic variables, pain, donation-related symptoms and recovery in 1211 related PBSC donors aged 18-79 enrolled in the Related Donor Safety Study (RDSafe). RD >60 had a lower median CD34+ level pre-apheresis compared to younger RD (age >60, 59 × 106 /L; age 41-60, 81 × 106 /L; age 18-40, 121 × 106 /L; p<0...
November 10, 2018: Biology of Blood and Marrow Transplantation
Hiroyuki Takamatsu, Takeshi Yamashita, Shingo Kurahashi, Takayuki Saitoh, Tadakazu Kondo, Takeshi Maeda, Hideyuki Nakazawa, Makoto Murata, Tomoko Narita, Junya Kuroda, Hisako Hashimoto, Koji Kawamura, Toshihiro Miyamoto, Sumihisa Honda, Tatsuo Ichinohe, Yoshiko Atsuta, Kazutaka Sunami
Conventional cytogenetic analyses and fluorescent in situ hybridization (FISH) are helpful for stratifying patients with multiple myeloma (MM) into high-risk [t(4;14), t(14;16), and/or del 17p] and standard-risk [t(11;14)] categories. However, the prognosis of patients with MM treated with autologous stem cell transplantation (ASCT) stratified according to these categories remains unclear. This retrospective observational study analyzed 97 patients with MM who received a single, planned ASCT after treatment with 200 mg/m2 melphalan between 2001 and 2011...
November 10, 2018: Biology of Blood and Marrow Transplantation
Usama Gergis, Emeline Masson Frenet, Tsiporah Shore, Sebastian Mayer, Adrienne Phillips, Jing-Mei Hsu, Gail Roboz, Ellen Ritchie, Joseph Scandura, Sangmin Lee, Pinkal Desai, Michael Samuel, Jeffrey Ball, Anthony Blanco, Cynthia Romeo, Maria S Albano, Ludy Dobrila, Andromachi Scaradavou, Koen van Besien
Adoptive immunotherapy has shown efficacy in patients with relapsed/refractory AML. We conducted a prospective evaluation of Cord Blood-based adoptive cell therapy following salvage chemotherapy in patients (pts) with AML/MDS and describe the safety and early outcomes of this approach. To enhance the anti-leukemic effect we selected Cord Blood Units (CBU) with shared Inherited Paternal Antigens (IPA) and/or Non-Inherited Maternal Antigens (NIMA) match with the recipients. Further, CBU had Total Nucleated Cell (TNC) dose < 2...
November 8, 2018: Biology of Blood and Marrow Transplantation
Janette Kwok, Patrick Chu, Charas Ong, Helen Ka-Wai Law, Patrick Ip, Cf Chan Godfrey, Iwei Lu
Cord blood (CB) is an alternative stem cell source for allogeneic haematopoietic stem cell transplantation (HSCT). The unique advantages with CB as a stem cell source lies in a degree of permissibility for human leukocyte antigen (HLA) mismatch, rapid availability, and relatively risk-free cell collection. Since HLA is highly polymorphic and population specific, optimal HLA matched unrelated donors or cord blood units (CBUs) may not be available. In view of the chance that matched CBUs which include non-inherited maternal antigens (NIMA) might contain acceptable HLA mismatches, we attempted to determine the degree of allo-reactivity of CB mononuclear cells (MNC) upon stimulation by the maternal, paternal and unrelated stimulator cells...
November 6, 2018: Biology of Blood and Marrow Transplantation
Sarah A Holstein, J Christine Ye, Alan Howard, Manisha Bhutani, Nicole Gormley, Theresa Hahn, Jens Hillengass, Amrita Krishnan, C Ola Landgren, Nikhil C Munshi, Stefania Oliva, Roger G Owen, Marcelo C Pasquini, Noemi Puig, Niels Weinhold, Katja Weisel, Philip L McCarthy
The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017 at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice...
November 5, 2018: Biology of Blood and Marrow Transplantation
Zachariah DeFilipp, Elizabeth Hohmann, Robert R Jenq, Yi-Bin Chen
Disruption of the intestinal microbiome early after allogeneic hematopoietic cell transplantation (allo-HCT) has been linked to adverse outcomes in transplant recipients. To date, it remains unknown as to whether microbiome-directed interventions will be able to impact important clinical endpoints. Fecal microbiota transplantation (FMT) is a compelling intervention to restore healthy diversity to the intestinal microenvironment after allo-HCT, but currently has no established role in transplant recipients. In this review, we examine the utilization of FMT as treatment for Clostridium difficile infections and acute graft-versus-host disease, as well as a restorative intervention early after allo-HCT...
November 5, 2018: Biology of Blood and Marrow Transplantation
Kavita Raj, Diderik-Jan Eikema, Donal P McLornan, Eduardo Olavarria, Henric-Jan Blok, Stefania Bregante, Fabio Ciceri, Jakob Passweg, Per Ljungman, Nicolaas Schaap, Kristina Carlson, Tsila Zuckerman, Liesbeth C de Wreede, Liisa Volin, Yener Koc, J Diez-Martin, Peter Brossart, Dominik Wolf, Didier Blaise, Paolo Di Bartolomeo, Antonin Vitek, Marie Robin, Yakoub-Agha I, Yves Chalandon, Nicolaus Kroger
This analysis includes 56 Myelofibrosis (MF) patients transplanted from family mismatched donor between 2009-2015 enrolled in the European Society for Blood and Marrow Transplantation (EBMT) database. The median age was 57 years (range, 38-72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8 × 106 /kg (1.7-22.9 × 106 /kg) (n=43)...
November 5, 2018: Biology of Blood and Marrow Transplantation
Christoph Groth, Lenneke F J van Groningen, Tiago R Matos, Manita E Bremmers, Frank W M B Preijers, Harry Dolstra, Christian Reicherts, Nicolaas P M Schaap, Eric H G van Hooren, Joanna IntHout, Rosalinde Masereeuw, Mihai G Netea, John E Levine, George Morales, James L Ferrara, Nicole M A Blijlevens, Ypke V J M van Oosterhout, Matthias Stelljes, Walter J F M van der Velden
Effective therapies for treating patients with steroid-refractory acute graft-versus-host-disease (SR-aGvHD), particularly strategies that reduce the duration of immunosuppression following remission, are urgently needed. The investigated immunotoxin-combination consists of a mixture of anti-CD3 and anti-CD7 antibodies separately conjugated to recombinant ricin A (CD3/CD7-IT), which induces in-vivo depletion of T- and NK-cells and suppresses T-cell receptor activation. We conducted a phase I/II trial in order to examine the safety and efficacy of CD3/CD7-IT in 20 patients with SR-aGvHD; 17 of these patients (85%) had severe SR-aGvHD, and all 20 patients had visceral organ involvement; 18 gastrointestinal (GI) (90%) and 5 liver (25%) involvement...
November 3, 2018: Biology of Blood and Marrow Transplantation
Laura Balligand, Claire Galambrun, Anne Sirvent, Clémence Roux, Cecile Pochon, Benedicte Bruno, Charlotte Jubert, Anderson Loundou, Sophie Esmiol, Ibrahim Yakoub-Agha, Edouard Forcade, Catherine Paillard, Aude Marie-Cardine, Dominique Plantaz, Virginie Gandemer, Didier Blaise, Fanny Rialland, Cecile Renard, Mylene Seux, Karine Baumstarck, Mohamad Mohty, Jean-Hugues Dalle, Gérard Michel
We previously reported in a French prospective randomized study that transplantation of 2 unrelated cord blood (UCB) units instead of 1 does not decrease the risk of transplantation failure but may enhance alloreactivity. We present here the influence of pre-transplant minimal residual disease (MRD) on leukemia relapse and survival after single versus double-UCB transplantation. Among 137 children and young adults who were transplanted in the randomized study, 115 had available MRD assessment immediately before their conditioning regimen...
October 29, 2018: Biology of Blood and Marrow Transplantation
Coco de Koning, Jurgen Langenhorst, Charlotte van Kesteren, Caroline A Lindemans, Alwin D R Huitema, Stefan Nierkens, Jaap Jan Boelens
Innate immune cells are the first to recover after allogeneic hematopoietic cell transplantation (HCT). Nevertheless, reports of innate immune cell recovery and their relation to adaptive recovery after HCT are largely lacking. Especially predicting CD4+ T cell reconstitution is of clinical interest, because this parameter directly associates with survival chances after HCT. We evaluated whether innate recovery relates to CD4+ T cell reconstitution probability and investigated differences between innate recovery after cord blood transplantation (CBT) and bone marrow transplantation (BMT)...
October 23, 2018: Biology of Blood and Marrow Transplantation
Daisuke Koyama, Makoto Murata, Ryo Hanajiri, Tomohiro Akashi, Shingo Okuno, Sonoko Kamoshita, Jakrawadee Julamanee, Erina Takagi, Kotaro Miyao, Reona Sakemura, Tatsunori Goto, Seitaro Terakura, Tetsuya Nishida, Hitoshi Kiyoi
Owing to the difficulty in isolating T cells from human biopsy samples, the characteristics of T cells that are infiltrating human acute graft-versus-host disease (GVHD) tissues remain largely uninvestigated. In the present study, TCR-β deep sequencing of various GVHD tissue samples and concurrent peripheral blood obtained from transplant recipients was performed in combination with functional assays of tissue-infiltrating T cell clones. The T cell repertoire was more skewed in GVHD tissues than in the peripheral blood...
October 22, 2018: Biology of Blood and Marrow Transplantation
Mizuki Watanabe, Junya Kanda, Masakatsu Hishizawa, Tadakazu Kondo, Kouhei Yamashita, Akifumi Takaori-Kondo
Viral infection is a serious complication that can greatly affect patient mortality and morbidity after allogenic hematopoietic stem cell transplantation (allo-HSCT). For the early identification of patients at high risk for viral infection, we evaluated the impact of lymphocyte area under the curve (AUC) value as a new predictive factor for early immune reconstitution after allo-HSCT against viral infection. This study included 286 patients who underwent their first allo-HSCT at Kyoto University Hospital between 2005 and 2017...
October 22, 2018: Biology of Blood and Marrow Transplantation
Ricardo Melendez-Munoz, Rachel Marchalik, Theresa Jerussi, Dimana Dimitrova, Veronique Nussenblatt, Andrea Beri, Khalid Rai, Jennifer S Wilder, A John Barrett, Minoo Battiwalla, Richard W Childs, Courtney D Fitzhugh, Daniel H Fowler, Terry J Fry, Ronald E Gress, Matthew M Hsieh, Sawa Ito, Elizabeth M Kang, Steven Z Pavletic, Nirali N Shah, John F Tisdale, Juan Gea-Banacloche, Christopher G Kanakry, Jennifer A Kanakry
Human cytomegalovirus (CMV) infection and disease remains a significant cause of morbidity and mortality for hematopoietic cell transplantation (HCT) recipients. Disruption of or weak reconstitution of virus-specific cellular immune function, such as with certain HCT approaches, poses significant risk for CMV-related complications. The incidence of and risk factors for CMV infection and the nature of CMV disease were evaluated retrospectively among 356 consecutive HCT recipients transplanted at the National Institutes of Health using all graft sources, including bone marrow, peripheral blood stem cell (PBSC), and umbilical cord blood (UCB), and a range of in vivo and ex vivo approaches for graft-versus-host disease (GVHD) prophylaxis...
October 18, 2018: Biology of Blood and Marrow Transplantation
Patrick J Hanley
No abstract text is available yet for this article.
October 18, 2018: Biology of Blood and Marrow Transplantation
Jessica Stokes, Emely A Hoffman, Megan S Molina, Jelena Eremija, Nicolas Larmonier, Yi Zeng, Emmanuel Katsanis
Graft-versus-host disease (GVHD) remains a significant challenge in allogeneic hematopoietic cell transplantation (HCT). An underinvestigated strategy to reduce GVHD is the modification of the preparative conditioning regimen. In the present study, we aimed to evaluate GVHD associated with bendamustine (BEN) conditioning in conjunction with total body irradiation (TBI) as an alternative to the standard myeloablative regimen of cyclophosphamide (CY) and TBI. We demonstrate that BEN-TBI conditioning, although facilitating complete donor chimerism, results in significantly less GVHD compared with CY-TBI...
October 13, 2018: Biology of Blood and Marrow Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"